Browse

Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used
AY.28 (Delta)	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.1.272	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.1.272	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.1.371	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.1.371	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
AA.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
AA.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.1.353	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.1.353	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.407	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.407	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XAJ	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XAJ	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.431	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.431	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
B.1.168	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
B.1.168	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
Q.6 (Alpha)	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
Q.6 (Alpha)	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
AZ.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
AZ.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BM.4.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BM.4.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.20	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.20	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.77	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.2.77	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
CP.1.3	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
CP.1.3	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
FC.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
FC.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
GY.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
GY.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XBF.10	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XBF.10	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
GA.8	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
GA.8	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XAY.1.1.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XAY.1.1.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XBB.1.38	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XBB.1.38	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
CT.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
CT.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XAY.1.1.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XAY.1.1.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.25.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.2.25.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XAD	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XAD	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XAB	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used